Seelos Therapeutics Inc (NASDAQ: SEEL) is making a run for the top in the market this morning. However, looking at the chart over the past month may send some mixed signals.
After reaching highs on March 12th, the stock has been falling recently. Nonetheless, it may be time to get involved. Today, we’ll talk about:
- Why I believe that now is the time to get involved in SEEL stock;
- what we’re seeing from the stock; and
- what we’ll be watching for ahead.
Now May Be The Time To Buy SEEL
As mentioned above, Seelos Therapeutics is having an incredibly strong start to the trading session this morning, but with no news out, some investors are scratching their heads. Nonetheless, I believe that there is a good reason for the gains and that the movement is likely to continue.
On March 12th, SEEL announced that it had acquired an exclusive license to intellectual property owned by The Regents of the University of California. The licensed property relates to a technology that was created by researchers at UCLA.
This technology surrounds a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (a-synuclein). The company plans on initially studying this approach in Parkinson’s disease.
However, SEEL also said that it plans on further evaluating the potential approach in other disorders that affect the central nervous system.
In my view, the new program, known as SLS-007 represents a strong potential opportunity. Early data shows that the method of action has the potential to yield incredible results in Parkinson’s disease and other disorders of the central nervous system.
Considering the mass markets that these disorders encompass, this could be a highly-valuable product, should it hit the market.
Following recent declines, and considering the value of the SLS-007 program, I believe that the stock is currently highly undervalued, representing an opportunity for compelling growth ahead.
What We’re Seeing From The Stock
While there has been no news issued by Seelos this morning, the stock is making a run for the top. The gains are likely the result of investors realizing the value of the company’s new asset under development, mixed with technical signals saying that the stock is currently undervalued.
Nonetheless, as is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:24), SEEL is trading at $3.05 per share after a gain of $0.25 per share or 8.93% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on SEEL. In particular, we’re interested in following the story surrounding the company’s continued work to develop SLS-007. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!